Navigation Links
Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
Date:4/22/2008

jects.

"The results of previous studies suggest that belimumab significantly reduced SLE disease activity in serologically active patients," said Professor Sandra V. Navarra, M.D., a principal investigator and head of Rheumatology at the University of Santo Tomas, Manila, Philippines. "There is a great need for better tolerated and more effective treatments for lupus, and we look forward to seeing the first Phase 3 data for belimumab by mid-2009."

About the LymphoStat-B Phase 3 Development Program

The LymphoStat-B Phase 3 development program includes two double-blind, placebo-controlled, multi-center Phase 3 superiority trials -- BLISS-52 and BLISS-76 -- to evaluate the efficacy and safety of LymphoStat-B plus standard of care, versus placebo plus standard of care, in patients with serologically active SLE. The design of the two trials is similar, but the duration of therapy in the two studies is different -- 52 weeks for BLISS-52 and 76 weeks for BLISS-76. The data from BLISS-76 will be analyzed after 52 weeks in support of a potential Biologics License Application (BLA). HGS designed the LymphoStat-B Phase 3 program in collaboration with GSK and leading international SLE experts.

"A total of nearly 1700 patients worldwide will be enrolled and randomized in the Phase 3 trials of belimumab, making this the largest double-blinded clinical development program ever undertaken in lupus patients," said William W. Freimuth, M.D., Ph.D., Vice President, Clinical Research - Immunology, Rheumatology and Infectious Diseases, HGS. "Today's milestone brings us closer to seeing Phase 3 data that we hope will confirm belimumab's promise as a potential treatment for patients with SLE. We are grateful for the superb performance of our clinical investigators, whose diligence made it possible to complete the enrollment of BLISS-52 ahead of our fall 2008 projection."

The primary efficacy endpoint of BLISS-52 and BLISS-76 is the patient response rate
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
2. Data Show SuperGens MP-470 is Safe in Humans
3. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
4. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
5. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
6. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
7. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 /PRNewswire/ ... announced the addition of Jain PharmaBiotech,s new ... Markets, and Companies" to their offering. ... transdermal drug delivery - an approach used ... therapeutic use as an alternative to oral,intravascular, ...
(Date:8/4/2015)... Concord Medical Services Holdings Limited ("Concord Medical", or the "Company") ... operator of the largest network of radiotherapy and diagnostic imaging ... will release its financial results for the second quarter of ... Management will hold a conference call to discuss the ... 18, 2015 (8:00 p.m. in Beijing / ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... The American College of Medical Genetics (ACMG) ... decision to make Critical Congenital Cyanotic Heart Disease (CCCHD) ... Secretary,s Advisory Committee on Heritable Disorders in Newborns and ... MD, FACMG had made the recommendations to Secretary Kathleen ...
... 2011 Visionsense Corp announces an unique milestone this ... 500th neurosurgical procedure with the VSii system. ... Vice-Chairman, Dept of Neurosurgery at Emory University and Professor ... of a pituitary adenoma in the morning of September ...
Cached Medicine Technology:American College of Medical Genetics Applauds HHS Secretary's Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease 2
(Date:8/4/2015)... , ... August 04, 2015 , ... ... which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their collegiate ... successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in ... millions of women every year. Dr. Angela DeRosa, DO, MBA, CPE aka ... therapies, takes the scary unknown out of menopause. , Myth #1: Menopause only ...
(Date:8/4/2015)... Diego, CA (PRWEB) , ... August 04, 2015 ... ... the Rise of Local Food,” scheduled for Nov. 3 – 4, 2015, at ... grow food sustainably, create new businesses, improve food access, and manage resources efficiently ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... 24/7 ... County, Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of ... indicate that 24/7 Care At Home’s agency is well on the path to meeting ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... label design, product packaging, and fulfillment services, joined over 200 other Long Island-based ... was held on Tuesday, July 28th at Jones Beach State Park in Wantagh, ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2
... President Obama and Secretary of State Clinton on today,s nomination ... the Global AIDS Coordinator (OGAC). AIDS Action is pleased ... led by such an accomplished HIV medical expert with extensive ... including the epidemic here in the United States. We ...
... 2009 (BRONX, NY) A laboratory study by researchers ... that an anti-cancer compound studied for treating blood cancers may ... The work is reported in the April 28th online edition ... neck cancer refers to tumors in the mouth, throat, or ...
... Findings from clinical studies used to gain Food and ... most patients with depression, according to a report led by ... in the May issue of the American Journal of ... people with depression qualify for these studies, and those who ...
... With growing concerns about the current spread of ... face masks protect against swine flu?"Tony Hanson, Managing Director ... an innovative, technologically advanced system of medical face masks ... this time it is believed that the current strain ...
... Inc. today announced that it named Dr. Robert Ruffolo, ... leader in pharmaceutical research to its Scientific Advisory Board. ... Development in 2008, and currently serves as a consultant ... and has been responsible for all pharmaceutical research and ...
... Embrace Use of Targeted Agents Despite Their High ... WALTHAM, Mass., April 28 Decision Resources, one ... focusing on pharmaceutical and healthcare issues, finds that ... Indian brand/generics (capecitabine) will dominate the Indian colorectal ...
Cached Medicine News:Health News:AIDS Action Applauds Selection of Dr. Eric Goosby as Global AIDS Coordinator 2Health News:Experimental drug shows promise against head and neck cancer 2Health News:Are we cherry picking participants for studies of antidepressants? 2Health News:Will Face Masks Protect Against Swine Flu? 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 3Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2
... the only dura material versatile enough for ... closure, and in cases where biological fixation ... in cases requiring an immediate watertight seal ... biological fixation and sealing are key factors ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Medicine Products: